Brief Report: Risk of Recurrent Interstitial Lung Disease From Osimertinib Versus Erlotinib Rechallenge After Symptomatic Osimertinib-Induced Interstitial Lung Disease
| Autor: | Li, Molly S.C., Lee, Kirsty W.C., Mok, Kevin K.S., Loong, Herbert H.F., Lam, K.C., Mok, Florence S.T., Chan, Landon L., Lau, Y.M., Chan, K.P., Ng, Joyce T.Y., Wong, Wesley K.Y., Lam, Benjamin H.W., Chen, Allen C.C., Lee, Matthew M.P., Chen, Olivia H., Mok, Tony S.K. |
|---|---|
| Zdroj: | In JTO Clinical and Research Reports April 2024 5(4) |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|